EUVIMEDEUVIMED entdecken
FallberichtOpen Access

HPV18 ‐Positive Cervical Large Cell Neuroendocrine Carcinoma With Rapid Progression Despite Pembrolizumab Combined With Chemotherapy: A Case Report With Immunogenomic Insights

Jumpei Ogura iD, Shimpei Sato, Yuichiro Koshida, Maya Kasuga, Takuya Yokoe iD, Naokazu Kanamoto

Journal of Obstetrics and Gynaecology Research · 2026

DOI: 10.1111/jog.70426 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2026. Verfasst von Jumpei Ogura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Saiseikai Noe Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Large Cell, Carcinoma, Neuroendocrine, Human papillomavirus 18. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HPV18‐positive cervical large cell neuroendocrine carcinoma (LCNEC) is exceptionally rare. We report a 40‐years‐old woman with FIGO 2018 stage IVB LCNEC who progressed rapidly despite paclitaxel–carboplatin–bevacizumab plus pembrolizumab, followed by concurrent chemoradiotherapy and later cytotoxic regimens. Biopsy showed chromogranin A and synaptophysin positivity, diffuse p16, and Ki‐67%~80%. Comprehensive profiling revealed very low tumor mutational burden (TMB, 1.21/Mb), microsatellite stability, no homologous recombination deficiency, and minimal PD‐L1 (~1%), consistent with a poorly immunogenic tumor microenvironment (TME). This profile may explain the limited effect of immune checkpoint inhibition in this histology. The case suggests that HPV or p16 positivity alone did not predict clinical benefit from pembrolizumab‐based therapy in advanced cervical LCNEC, and supports careful biological assessment before treatment selection. These observations provide practical guidance for clinicians and support evaluation of alternative or investigational strategies for this aggressive tumor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Large CellCarcinoma, NeuroendocrineHuman papillomavirus 18Papillomavirus InfectionsUterine Cervical NeoplasmsAdultFemaleHumansAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalDisease Progression

Stichwörter der Autor:innen

biopsycervical cancerchromogranin Aimmune checkpointlarge‐cell neuroendocrine cancerneuroendocrine cervical carcinomaoncologypembrolizumabsynaptophysintumor microenvironment

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumab

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Saiseikai Noe Hospital, Osaka, Japan.

ORCID-Profile: Jumpei Ogura, Takuya Yokoe

Zitieren

APA

Ogura, J., Sato, S., Koshida, Y., Kasuga, M., Yokoe, T., & Kanamoto, N. (2026). HPV18 ‐Positive Cervical Large Cell Neuroendocrine Carcinoma With Rapid Progression Despite Pembrolizumab Combined With Chemotherapy: A Case Report With Immunogenomic Insights. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.70426

Vancouver

Ogura J, Sato S, Koshida Y, Kasuga M, Yokoe T, Kanamoto N. HPV18 ‐Positive Cervical Large Cell Neuroendocrine Carcinoma With Rapid Progression Despite Pembrolizumab Combined With Chemotherapy: A Case Report With Immunogenomic Insights. Journal of Obstetrics and Gynaecology Research. 2026. doi:10.1111/jog.70426

BibTeX
@article{Ogura2026,
  author = {Ogura, Jumpei and Sato, Shimpei and Koshida, Yuichiro and Kasuga, Maya and Yokoe, Takuya and Kanamoto, Naokazu},
  title = {HPV18 ‐Positive Cervical Large Cell Neuroendocrine Carcinoma With Rapid Progression Despite Pembrolizumab Combined With Chemotherapy: A Case Report With Immunogenomic Insights},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2026},
  doi = {10.1111/jog.70426}
}
Kostenlos starten →